#POSLUMA
LightNews LightNews
dximaging-mjh.bsky.social
What New Research Reveals About Posluma for Detecting Biochemical Recurrence and Bone Metastasis in PCa
www.diagnosticimaging.com/view/new-res...
#radiology #RadRes #GU26 #ProstateCancer
March 2, 2026 at 8:46 PM
newsen.bsky.social
Blue Earth Diagnostics Presents Promising Study Results for Prostate Cancer Imaging with POSLUMA#USA#Boston#Prostate_Cancer#Blue_Earth_Diagnostics#POSLUMA
Blue Earth Diagnostics Presents Promising Study Results for Prostate Cancer Imaging with POSLUMA
Recent head-to-head research by Blue Earth Diagnostics highlights the effectiveness of POSLUMA in detecting prostate cancer recurrence, outperforming Piflufolastat.
third-news.com
February 27, 2026 at 5:56 PM
newsen.bsky.social
Blue Earth Diagnostics to Showcase Key Research on POSLUMA® at ASCO 2026#United_States#San_Francisco#Prostate_Cancer#Blue_Earth_Diagnostics#POSLUMA
Blue Earth Diagnostics to Showcase Key Research on POSLUMA® at ASCO 2026
Blue Earth Diagnostics will present the latest findings on PESLUMA® (flotufolastat F 18) in prostate cancer at ASCO 2026, highlighting its innovative imaging capabilities.
third-news.com
February 18, 2026 at 3:15 PM
l2plabs.bsky.social
Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in Men with Biochemical Recurrence of Prostate Cancer
BOSTON, Feb. 27, 2026 /PRNewswire/ -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results from the first head-to-head study comparing urinary...
dlvr.it
February 27, 2026 at 2:03 PM
l2plabs.bsky.social
Blue Earth Diagnostics to Highlight New POSLUMA® (Flotufolastat F 18) Study Results in Prostate Cancer at the 2026 ASCO Genitourinary Symposium (ASCO GU)
BOSTON, Feb. 18, 2026 /PRNewswire/ -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced that multiple presentations featuring POSLUMA®...
dlvr.it
February 18, 2026 at 2:05 PM